Skip to content

Prospective long-term evaluation of the performance and safety of Calistar S for transvaginal pelvic organ prolapse repair

Prospective, multicenter, 60 months, single arm cohort study to evaluate the efficacy and safety of the Ultra-Light-Weight mesh CAlistar S in transvaginal Pelvic Organ Prolapse repair

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28804
Enrollment
179
Registered
2021-10-25
Start date
2021-12-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Pelvic Organ Prolapse

Interventions

Calistar S for transvaginal pelvic organ prolapse repair

Sponsors

AMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Non-pregnant women > 18 years defined by postmenopausal status and / or iatrogenic causes which exclude women permanently from becoming pregnant (e.g. history of hysterectomy or sterilised women). 2. Anterior prolapse with or without apical vaginal wall involvement according POP-Q score = 2 3. Subjects with recurrent prolapse as well as primary complex prolapse when other surgical procedures are expected to fail (i.e. high risk for recurrence) are eligible for the study. 4. Scheduled mesh-augmented anterior POP repair with Calistar S

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Patients with active or latent infection of the vagina, cervix or uterus 3. Patients with previous or current vaginal, cervical or uterine cancer 4. Previous, current or planned pelvic radiation therapy 5. Known allergy to polypropylene 6. Ulcus of the vaginal wall 7. Subject is unable or unwilling to complete questionnaires (either self-administered, assisted or interviewed) and/or to follow scheduled visits and/or to sign informed consent

Design outcomes

Primary

MeasureTime frame
Number of patients with surgical treatment success of anterior and apical pelvic organ prolapse after 24 months

Secondary

MeasureTime frame
Quality of life, sexual function, complication rates, revision and explantation free survival, surgical treatment for urinary stress incontinence, cure in short, mid-term, and long-term follow-Up.

Contacts

Public ContactGert-Jan van Baaren

AMC

calistars@amsterdamumc.nl0205669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)